148 related articles for article (PubMed ID: 35588468)
1. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era.
Niemann CU; da Cunha-Bang C; Helleberg M; Ostrowski SR; Brieghel C
Blood; 2022 Aug; 140(5):445-450. PubMed ID: 35588468
[TBL] [Abstract][Full Text] [Related]
2. Improved outcomes in patients with chronic lymphocytic leukaemia infected during the omicron BA.5 subvariant surge.
Bronstein Y; Levi S; Herishanu Y
Br J Haematol; 2023 Jun; 201(6):1125-1128. PubMed ID: 37042235
[TBL] [Abstract][Full Text] [Related]
3. Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
Iuliano AD; Brunkard JM; Boehmer TK; Peterson E; Adjei S; Binder AM; Cobb S; Graff P; Hidalgo P; Panaggio MJ; Rainey JJ; Rao P; Soetebier K; Wacaster S; Ai C; Gupta V; Molinari NM; Ritchey MD
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(4):146-152. PubMed ID: 35085225
[TBL] [Abstract][Full Text] [Related]
4. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.
Modes ME; Directo MP; Melgar M; Johnson LR; Yang H; Chaudhary P; Bartolini S; Kho N; Noble PW; Isonaka S; Chen P
MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(6):217-223. PubMed ID: 35143466
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Omicron Variant in Patients With Chronic Lymphocytic Leukemia: Case Series.
Khamees I; Ali EA; Malkawi L; Rozi W; Yassin MA
Cureus; 2022 Nov; 14(11):e32041. PubMed ID: 36600852
[TBL] [Abstract][Full Text] [Related]
6. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
Strasser ZH; Greifer N; Hadavand A; Murphy SN; Estiri H
JAMA Netw Open; 2022 Oct; 5(10):e2238354. PubMed ID: 36282501
[TBL] [Abstract][Full Text] [Related]
7. In silico evaluation of the impact of Omicron variant of concern sublineage BA.4 and BA.5 on the sensitivity of RT-qPCR assays for SARS-CoV-2 detection using whole genome sequencing.
Sharma D; Notarte KI; Fernandez RA; Lippi G; Gromiha MM; Henry BM
J Med Virol; 2023 Jan; 95(1):e28241. PubMed ID: 36263448
[TBL] [Abstract][Full Text] [Related]
8. Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic.
Arellano-Llamas AA; Vela-Ojeda J; Hernandez-Caballero A
Curr Oncol Rep; 2022 Feb; 24(2):209-213. PubMed ID: 35061199
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of nirmatrelvir plus ritonavir treatment for patients with chronic lymphocytic leukemia during the Omicron surge.
Tadmor T; Alapi H; Rokach L
Blood; 2023 May; 141(18):2239-2244. PubMed ID: 36848657
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 vaccinations and rates of infections, hospitalizations, ICU admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022.
Rzymski P; Kasianchuk N; Sikora D; Poniedziałek B
J Med Virol; 2023 Jan; 95(1):e28131. PubMed ID: 36068643
[TBL] [Abstract][Full Text] [Related]
12. Milder disease trajectory among COVID-19 patients hospitalised with the SARS-CoV-2 Omicron variant compared with the Delta variant in Norway.
Stålcrantz J; Kristoffersen AB; Bøås H; Veneti L; Seppälä E; Aasand N; Hungnes O; Kvåle R; Bragstad K; Buanes EA; Whittaker R
Scand J Public Health; 2022 Aug; 50(6):676-682. PubMed ID: 35799474
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a light at the end of the tunnel?
Mattiuzzi C; Henry BM; Lippi G
Int J Infect Dis; 2022 May; 118():167-168. PubMed ID: 35278677
[TBL] [Abstract][Full Text] [Related]
14. Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022.
Havers FP; Patel K; Whitaker M; Milucky J; Reingold A; Armistead I; Meek J; Anderson EJ; Weigel A; Reeg L; Seys S; Ropp SL; Spina N; Felsen CB; Moran NE; Sutton M; Talbot HK; George A; Taylor CA;
MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(34):1085-1091. PubMed ID: 36006841
[TBL] [Abstract][Full Text] [Related]
15. Signals of Significantly Increased Vaccine Breakthrough, Decreased Hospitalization Rates, and Less Severe Disease in Patients with Coronavirus Disease 2019 Caused by the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2 in Houston, Texas.
Christensen PA; Olsen RJ; Long SW; Snehal R; Davis JJ; Ojeda Saavedra M; Reppond K; Shyer MN; Cambric J; Gadd R; Thakur RM; Batajoo A; Mangham R; Pena S; Trinh T; Kinskey JC; Williams G; Olson R; Gollihar J; Musser JM
Am J Pathol; 2022 Apr; 192(4):642-652. PubMed ID: 35123975
[TBL] [Abstract][Full Text] [Related]
16. COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study.
Thau S; Poulsen CB; Brieghel C; Larsen MK; Wiese L; Nielsen XC; Pedersen LM
Ann Hematol; 2024 Apr; ():. PubMed ID: 38634916
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of COVID-19 patients during B.1.1.529 (Omicron) dominance compared to B.1.617.2 (Delta) in 89 German hospitals.
Leiner J; Pellissier V; Hohenstein S; König S; Schuler E; Möller R; Nachtigall I; Bonsignore M; Hindricks G; Kuhlen R; Bollmann A
BMC Infect Dis; 2022 Oct; 22(1):802. PubMed ID: 36303111
[TBL] [Abstract][Full Text] [Related]
18. Transmissibility, hospitalization, and intensive care admissions due to omicron compared to delta variants of SARS-CoV-2 in Catalonia: A cohort study and ecological analysis.
Català M; Coma E; Alonso S; Andrés C; Blanco I; Antón A; Bordoy AE; Cardona PJ; Fina F; Martró E; Medina M; Mora N; Saludes V; Prats C; Prieto-Alhambra D; Alvarez-Lacalle E
Front Public Health; 2022; 10():961030. PubMed ID: 36033822
[TBL] [Abstract][Full Text] [Related]
19. THE COURSE OF CHRONIC LYMPHOCYTIC LEUKEMIA AFTER SARS-COV-2 VIRUS INFECTION.
Dyagil IS; Abramenko IV; Martina ZV; Golyarnic NA; Brychenko VV; Movchan AV; Chumak AA; Bazyka DA
Probl Radiac Med Radiobiol; 2023 Dec; 28():267-276. PubMed ID: 38155128
[TBL] [Abstract][Full Text] [Related]
20. Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant in Patients with Philadelphia-Negative Myeloproliferative Neoplasm: A Single Center Experience.
Ali EAH; Khamees I; Alshurafa A; Qasim H; Abu-Tineh MA; Ahmed K; Saad E; Yassin M
Oncology; 2022; 100(8):460-466. PubMed ID: 35882185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
